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Abstract
We have investigated the frequency of methylation of several tumour suppressor
genes in uveal melanoma. As the loss of one copy of chromosome 3 (monosomy 3),
which is found in about half of these tumours, is tightly associated with metastatic
disease, a special emphasis was laid on genes located on this chromosome, including
the fragile histidine triad (FHIT), von Hippel–Lindau (VHL), β-catenin (CTNNB1),
activated leukocyte cell adhesion molecule (ALCAM) and retinoic acid receptor-β2
(RARB) genes. In addition, the methylation patterns of the CpG-rich regions 5 
of the E-cadherin (CDH1), p16/cyclin-dependent kinase inhibitor 2 A (CDKN2A)
and retinoblastoma (RB1) genes were analysed by bisulphite genomic sequencing or
methylation-speciﬁc PCR (MSP). Furthermore, the SNRPN and D15S63 loci, which
are located in the imprinted region of chromosome 15, were included in the study.
Aberrant methylation was detected in nine of 40 tumours analysed: The imprinted
SNRPN and D15S63 loci were hypermethylated in three tumours, all of which retained
both copies of chromosome 3. Methylated RARB alleles were detected in three
tumours, whereas in three other tumours CDKN2A was found to be methylated.
As we did not ﬁnd RARB and CDKN2A preferentially methylated in tumours with
monosomy 3, which is a signiﬁcant predictor of metastatic disease, we suggest that
these genes may play a causative role in the formation of uveal melanoma but not in
the development of metastases. Copyright  2003 John Wiley & Sons, Ltd.
Keywords: uveal melanoma; metastatic disease; tumour suppressor gene; DNA
methylation; chromosome 3
Introduction
Uveal melanoma is the most common form of pri-
mary eye cancer, with an incidence of six cases
per million people per year. About 50% of these
tumours show loss of an entire chromosome 3.
This chromosomal aberration is signiﬁcantly asso-
ciated with metastatic disease. In long-term studies,
approximately 70% of patients with monosomy 3
in the primary tumour died of metastases, whereas
tumours having two normal copies of chromosome
3 (disomy 3) rarely gave rise to metastatic disease
(Prescher et al., 1998; White et al., 1998a; Sisley
et al., 1997). The molecular mechanisms underly-
ing uveal melanoma development, progression and
metastasis are yet unknown. Assuming that loss of
one chromosome 3 is part of a two-step inactiva-
tion mechanism typical of tumour suppressor genes
(TSGs), one would expect that metastasizing uveal
melanoma depends on biallelic inactivation of one
or more genes located on chromosome 3. This
hypothesis is backed by the ﬁnding of common
regions of deletion overlap in tumours that have
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lost only parts of chromosome 3 (Tschentscher
et al., 2001). Alternatively, as uveal melanomas
occasionally show isodisomy (two identical copies)
of chromosome 3, the possible role of epigenetic
mechanisms has been put forward (White et al.,
1998b). However, no imprinted regions have been
reported on chromosome 3 so far.
De novo DNA methylation is an epigenetic alter-
ation that has been found to contribute to the devel-
opment and progression of several tumours (for
review, see Baylin et al., 2001). Aberrant methy-
lation frequently targets CpG-rich regions (CpG
islands) at the 5  end of genes. With the exception
of CpG islands associated with imprinted genes, or
genes located on the inactive X chromosome, these
regions are maintained free of methylation in nor-
mal cells. The RB1 gene, which was the ﬁrst TSG
shown to be methylated in tumours (Greger et al.,
1989; Sakai et al., 1991), shows allele-speciﬁc epi-
genetic alterations in about 10% of retinoblas-
tomas (Klutz et al., 1999). Promoter methylation
can result in the inactivation of genes, and therefore
putative TSGs can be identiﬁed using methylation
analysis of tumour DNA.
To analyse the role of DNA methylation in
uveal melanoma, we have analysed the methyla-
tion status of the known or putative promoter/exon
1 regions of eight genes known to be involved
in tumourigenesis, and two imprinted loci, in 40
uveal melanomas. In view of the strong associa-
tion of monosomy 3 with metastatic disease, the
methylation status of genes on this chromosome
was of particular interest. We investigated the frag-
ile histidine triad gene (FHIT), a putative TSG
located in chromosome region 3p14.2, the retinoic
acid receptor-β2 gene (RARB, on 3p24), the VHL
gene (3p25), the activated leukocyte cell adhe-
sion molecule gene (ALCAM, on 3q13) and the β-
catenin gene (CTNNB1, on 3p21). We also included
the E-cadherin gene (CDH1, on 16q22) in our
study, as loss of function of the complex formed
by β-catenin and E-cadherin occurs in a variety of
epithelial tumours and is correlated with invasion
and metastasis (Yap, 1998). In addition, CDH1 was
found to be expressed in a variable manner in uveal
melanoma (Anastassiou et al., 2001).
We also analysed the methylation status of the
RB1 (13q14) and CDKN2A (9p21) genes, which
are involved in tumourigenesis of several tumours,
including uveal melanoma. In previous studies,
CDKN2A methylation was reported in 6% (Merbs
and Sidransky, 1999) to 34% (Van der Velden
et al., 2001) of uveal melanomas. Recently, loss
of heterozygosity (LOH) at the RB1 locus was
found to be a common alteration (21%) in uveal
melanomas (Scholes et al., 2001), suggesting a role
for RB1, or additional loci close to RB1, in uveal
melanoma tumourigenesis.
Finally, we investigated the SNRPN and D15S63
loci, which are located in the imprinted region of
chromosome 15. This region, which is affected
in patients with Prader–Willi or Angelman syn-
dromes, is not known to play a role in tumour
formation but we were interested to know whether
imprint maintenance is affected in tumour cells.
Materials and methods
Patients and biopsy specimens
Diagnosis of uveal melanoma was established fol-
lowing current ophthalmological and histological
criteria. Vital tumour samples were obtained from
patients treated by primary enucleation without
prior radiation or chemotherapy. Peripheral blood
and tumour material were obtained at the time of
operation and stored at −80 ◦C.
Analysis of chromosome 3 status
DNA extractions from blood and tumour samples
and PCR-based diagnosis of chromosome 3
loss were carried out as described previously
(Tschentscher et al., 2000; 2001). In brief,
ﬂuorescently labelled primers were used for
ampliﬁcation of the microsatellites D3S3050,
D3S2406, D3S3045, D3S1744, D3S2421, D3S1311
and D3S1272 from the DNA of tumours
and corresponding blood samples, in individual
reactions. Reaction products were analysed using
an ABI 3100 automated capillary genetic analyser
and the GeneScan and Genotyper software
(Applied Biosystems, Foster City, CA). According
to the report by Tschentscher et al. (2000), uveal
melanomas showing LOH for all informative
markers on chromosome 3 were considered to have
monosomy 3.
Bisulphite treatment
Bisulphite modiﬁcation was performed as described
(Clark et al., 1994). Brieﬂy, tumour DNA (5 µg
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in 50 µl) was denatured by adding 6 µl freshly
prepared 3 M NaOH and incubating the solution
at 37 ◦C for 15 min. For complete denaturation,
the samples were incubated at 95 ◦C for 1 min and
subsequently cooled on ice. The bisulphite solution
was prepared by dissolving 8.1 g sodium bisul-
phite in 16 ml H2O, adding 1 ml 40 mM hydrochi-
none solution and adjusting the pH to 5.0 with
600 µl1 0M NaOH; 0.5 ml bisulphite solution was
mixed with the denatured DNA, overlaid with min-
eral oil, and incubated at 55 ◦C for 16–18 h in
a water bath in the dark. The DNA was recov-
ered using the Wizard DNA Clean-Up System
(Promega, Mannheim, Germany) and eluted in
100 µlH 2O. Following this, 11 µl3M NaOH was
added and the sample was incubated for 15 min
at 37 ◦C. The solution was then neutralized by
adding 110 µl6 M NH4OAc, pH 7.0. The DNA
was ethanol-precipitated, washed in 70% ethanol,
dried and resuspended in 40 µlH 2O. Bisulphite
treated DNA (2 µl) was used in each of the PCR
assays.
Methylation-speciﬁc PCR (MSP)
Established MSP protocols were used to analyse
the methylation status of the VHL, CDH1,
CDKN2A (primers p16-U2 and p16-M2; for
sequence, see Herman et al., 1996) and RB1 pro-
moter/exon 1 regions, as well as the imprinted
SNRPN and D15S63 loci (Herman et al., 1996;
Zeschnigk et al., 1997, 1999; Runte et al.,
2001). The RARB-MSP was modiﬁed from Wid-
schwendter et al. (2000). PCR was performed
i na2 5 µl reaction volume containing 2 µl
bisulphite-treated DNA. The conditions were
10 mM Tris–HCl, pH 8.3, 50 mM KCl, 1.5 mM
MgCl2,5 0µM of each dNTP and 0.5 U AmpliTaq
(Applied Biosystems, Foster City, USA). For
the detection of methylated alleles, 1 µM each
primer (RAR–MAS and RAR–MES) was used;
for the detection of unmethylated alleles, we used
1 µM each primer (RAR–UAS and RAR–USE)
in a separate reaction. After the initial denat-
uration step at 94 ◦C for 5 min, 35 cycles of
denaturation (at 95 ◦C for 15 s), annealing (at
60 ◦C for 30 s) and extension (at 72 ◦Cf o r
30 s) were performed, followed by a ﬁnal exten-
sion (at 72 ◦C for 5 min). MSP products were
separated on 2.5% agarose gels and visual-
ized by ethidium bromide staining. The primer
sequences used were as follows: RAR–MSE: 5 -
ATGTCGAGAACGCGAGCGATTC-3  (nt 102–
123); RAR–MAS: 5 -CTCGACCAATCCAACCG-
AAACG-3  (nt 232–253); RAR–USE: 5 -GGATG-
TTGAGAATGTGAGTGATTT-3  (nt 100–123);
RAR–UAS: 5 -TACTCAACCAATCCAACCA-
AAACA-3  (nt 232–255). The nucleotide posi-
tions of the primers are given according to Wid-
schwendter et al. (2000).
Genomic sequencing
PCRs for the ALCAM analysis were performed
with the primers ALCAM5  and ALCAM3  (Table
1), which were designed to bind to the putative
promoter/exon 1 region (GenBank Accession Nos
L38608 and AC078806) in bisulphite-treated DNA.
The primer sequences for CTNNB1 (CTNNB5  and
CTNNB3 ) and FHIT (FHITas5  and FHITas3 )
ampliﬁcation were generated on the basis of pub-
lished sequence data (GenBank Accession Nos
X89448 and U76262/U76263, respectively). These
primer sequences are all given in Table 1. PCRs
for methylation analysis of these genes were per-
formed under the conditions given above for the
Table 1. The primers used for genomic sequencing
Primer Sequence Accession Position (nt) Annealing (C◦)
FHITas5  GTTTTTATTTTTTAGGATGTTGATAGTTGG U76262 1413–11442 60
FHITas3  AATTACTATCACTATAACTTTCAATTAACC U76263 129–158 60
CTNNB5  TATTTTAAGTTTTTc/tGGTTTGTGGTAGTAG X89448 990–1020 64
CTNNB3  CAAACACCTCAAAAAAACAAACTCCTCC X89448 1142–1170 64
ALCAM5  ATTATTTAAGTGTTTTTTGGAAATAGAGGG AC078806 73938–73968 64
ALCAM3  TTCCATATTCCTCCTCCTTCTTAATAAACC AC078806 74217–74247 64
All primer sequences are given in the 5  to 3  orientation. The primers were designed based on the sequence information (accession) provided
by GenBank database at NCBI. The primer positions (position) according to the GenBank data ﬁle and annealing temperatures (annealing)
used for PCR are also given. c/t, C and T were added in equal concentration during primer synthesis.
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RARB–MSP; however, the primer concentrations
were adjusted to 0.8 µM each. After the initial
denaturation step (at 94 ◦C for 5 min), 35 cycles of
denaturation (at 95 ◦C for 15 s), annealing (at 60 ◦C
for the FHIT PCR and 64 ◦Cf o rt h eALCAM and
CTNNB PCR for 15 s) and extension (at 72 ◦Cf o r
15 s) were performed, followed by a ﬁnal exten-
sion step (at 72 ◦C for 5 min). PCR products were
separated on 2.5% agarose gels and visualized by
ethidium bromide staining. Agarose gel slices con-
taining PCR products were excised from the gels
and puriﬁed using the MiniElute Extraction Kit
(Qiagen, Hilden, Germany).
DNA sequencing
ALCAM, FHIT and CTNNB PCR products were
sequenced using an ABI 3100 automated capil-
lary genetic analyser (Applied Biosystems, Foster
City, CA), using the corresponding 3  primers as
sequencing primers. To enable the SequenceAna-
lyse software for automated analysis, 1 µlM a t r i x
Standard Set DS-01 (Applied Biosystems, Foster
City, CA) was added to each sample before load-
ing it onto the machine. As the sequence reactions
were started with the 3  primer, formerly methy-
lated cytosines were indicated by a G-peak in the
electropherogram.
Results
Established MSP protocols were used to anal-
yse the methylation status of the VHL, CDH1,
CDKN2A,RARB, and RB1 promoter/exon 1 regions
as well as the imprinted SNRPN and D15S63
loci (Herman et al., 1996; Zeschnigk et al., 1997,
1999; Runte et al., 2001). The accuracy of MSP
was controlled by the use of methylated control
DNA as a template. To determine the methyla-
tion patterns of the FHIT, CTNNB1 and ALCAM
genes, we generated PCR primers (Table 1) that
hybridize to bisulphite-treated DNA in the corre-
sponding promoter/exon 1 regions. After perform-
ing PCR on bisulphite-modiﬁed genomic tumour
DNA and methylated control templates, the PCR
products were puriﬁed and sequenced. The use of
premethylated DNA as a control conﬁrmed that all
of the assays were capable of detecting methylated
alleles.
The methylation status of all 10 loci was tested
in 40 tumour samples, 50% of which had mono-
somy 3. Detection of any methylation in non-
imprinted CpG islands is described as methylated.
As summarized in Table 2, none of the tumours
showed methylation in the promoter/exon 1 regions
of the FHIT, CTNNB1, VHL, ALCAM, CDH1 and
RB1 genes. Two tumours with disomy 3 (T21 and
T22) and one tumour with monosomy 3 (T15)
showed methylation of the RARB gene on chro-
mosome 3 (Figure 1a). In addition to a methy-
lated allele, the MSP displayed the presence of an
unmethylated allele in these tumours. The observa-
tion of two RARB alleles appears to be in conﬂict
with the presence of monosomy 3 in tumour T15,
but could be explained by methylation mosaicism.
The CDKN2A promoter region was methylated
in three different tumours, one tumour with mono-
somy 3 (T16) and two tumours with disomy 3 (T25,
T36) (Figure 1b). In all three tumours, in addition
to the methylated allele, a PCR product speciﬁc for
an unmethylated allele was present.
The imprinted loci SNRPN and D15S63 are
known to be methylated on the maternal chromo-
some, and unmethylated on the paternal chromo-
some, in normal individuals. Surprisingly, the PCR
product speciﬁc for the unmethylated D15S63 alle-
les (143 bp) was absent in two tumours (T27 and
T35), and a third tumour (T24) showed only a
weak signal. In one of these tumours (T27), the
PCR product speciﬁc for the unmethylated SNRPN
allele (221 bp) was also reduced (Figure 2). These
results are compatible with the assumption of de
novo methylation of the paternal D15S63 alle-
les in the tumours. Alternatively, they may be
explained by loss of the paternal D15S63 allele.
However, LOH is unlikely for tumours T24 and
T35, because both show two differentially methy-
lated alleles at the closely linked SNRPN locus.
It is noteworthy that the altered methylation of
the SNRPN/D15S63 region was only observed in
tumours with disomy 3.
In summary, aberrant methylation was detected
in nine out of 40 primary uveal melanomas and was
restricted to the TSGs RARB and CDKN2A and
the imprinted region on chromosome 15. Altered
methylation was less frequent in tumours with
monosomy 3 (2/20) than in tumours with disomy
3 (7/20).
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Discussion
To identify TSGs in uveal melanoma, we anal-
ysed the methylation status of the promoter/exon
1 regions of a set of TSGs in 40 tumour samples.
As the loss of chromosome 3 in this tumour is
associated with metastatic disease and poor sur-
vival, we focused our study on genes located
on chromosome 3. No methylation was present
in the CpG islands of the VHL, FHIT, CTNNB1
and ALCAM genes, which are located on chromo-
some 3. While methylation-mediated silencing of
CTNNB1 and ALCAM have not previously been
reported in any tumour, VHL and FHIT are known
to be inactivated by promoter methylation in a wide
range of other tumour entities, indicating that this
alteration is a common inactivation mechanism of
both TSGs. The absence of this epigenetic modiﬁ-
cation in 40 uveal melanomas makes a major role
of VHL und FHIT in uveal melanoma tumourige-
nesis unlikely.
Three uveal melanomas showed methylation of
RARB, which is thought to function as a TSG (Liu
et al., 1996; Houle et al., 1993). This gene was
shown to be inactivated by methylation in 38%
of primary breast cancers Widschwendter et al.
(2000) and 40% of primary non-small cell lung
cancers (Z¨ ochbauer-M¨ uller et al., 2001). Although
the frequency of RARB methylation is much lower
in uveal melanomas (7.5%), our results suggest
that RARB may be involved in uveal melanoma
formation. However, it is unlikely that RARB is
a major gene involved in metastatic disease in
tumours with monosomy 3, because two of the
three uveal melanomas with methylation of RARB
have disomy 3, and methylation in the tumour
with monosomy 3 is present in only some of the
cells.
Among the 40 uveal melanomas investigated
here, three (7.5%) showed methylation of
CDKN2A. The frequency of CDKN2A methylation
in our study corresponds well to the ﬁndings of
Merbs et al. (1999), who identiﬁed methylated
CDKN2A alleles in two out of 33 uveal melanomas
(6%), but it is in contrast to the results of van der
Velden et al. (2001), who investigated 22 tumours
and found CDKN2A methylation in 34% of them.
In all three studies, MSP was used to determine the
methylation status, and we have no explanation for
the discrepancy between these results. Moreover,
van der Velden et al. found an association between
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Figure 1. Methylation-speciﬁc PCR of bisulphite treated primary uveal melanoma DNAs (T) and methylated control DNA
(meth. contr.) using primers speciﬁc for methylated (M) and unmethylated (U) DNA, respectively. A PCR product in lanes
marked with a U indicates the presence of an unmethylated allele, and in lanes marked with an M indicates the presence
of a methylated allele. The PCR product sizes of the RARB (a) and CDKN2A (b) alleles are 152 bp and 234 bp, respectively.
Marker (MW) = MspI-digested pUC19 DNA; PCR products were separated on a 2.5% agarose gel
uveal melanomas controls
331bp
242 bp
190 bp
147 bp
MW T8 T24 T27 T35 NP PWS AS
SNRPN
D15S63
methylated
unmethylated
methylated
unmethylated
Figure 2. Analysis of the imprinted SNRPN and D15S63 loci. A single-tube MSP assay was performed on bisulphite-treated
primary uveal melanoma DNAs (T) and DNA from blood cells from Prader–Willi (PWS) or Angelman syndrome (AS)
patients and a normal control (NP). A normal methylation status is reﬂected by two PCR products with sizes 221 bp and
313 bp for the SNRPN, and two PCR products of 143 bp and 161 bp for the D15S63 loci. Marker (MW) = MspI-digested
pUC19 DNA. The MSP products were separated on 3% agarose gels
CDKN2A methylation and tumour location and
presence of epithelioid cells, which are prognostic
factors for metastatic disease. In our tumour set,
however, CDKN2A methylation was not associated
with monosomy 3, which is the best predictor of
metastatic disease known so far.
Recently, LOH at a polymorphic locus within
the RB1 gene was found in ﬁve (21%) out of
27 uveal melanomas, suggesting that this gene is
involved in the pathogenesis of uveal melanoma
(Scholes et al., 2001). In retinoblastoma, a tumour
that invariably shows biallelic inactivation of the
RB1 gene, methylation is observed in 10% of
tumours. As we did not ﬁnd methylated RB1 alleles
in 40 analysed samples, this gene is most likely not
the TSG targeted by the LOH at 13q14 in uveal
melanoma. As discussed by Scholes et al. (2001),
a locus closely linked to, but distinct from, RB1
may be involved.
In several tumour types, the loss of E-cadherin
is associated with invasive disease and metastasis.
In uveal melanomas, this gene was found to show
varying levels of expression, at both the RNA
and the protein level (Anastassiou et al., 2001). As
we found no methylated CDH1 alleles among 40
tumours, the low expression of this gene in some
uveal melanomas is most probably not caused by
promoter methylation.
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We found alterations in the DNA methylation of
the imprinted region on chromosome 15 in three
uveal melanomas, all with disomy 3. In one tumour
(T27), both SNRPN and D15S63 appeared to be
hypermethylated. In principle, the absence of an
unmethylated allele in the tumours can be due to
loss of heterozygosity; however, the presence of
two differentially methylated alleles at the closely
linked SNRPN locus in tumour T24 and T35
shows that altered D15S63 methylation is the likely
cause of the observed results in these tumours.
Interestingly, alterations of the SNRPN/D15S63
methylation pattern were restricted to tumours with
disomy 3, which correlates with a good prognosis.
In a previous study (Dittrich et al., 1993), we found
various degrees of D15S63 hypomethylation in
different tumours. As D15S63 and SNRPN are
unlikely to play a role in tumour formation, it is
likely that these changes reﬂect loss of imprint
maintenance caused by tumour formation.
In summary, our data indicate that methylation
of known tumour suppressor genes is infrequent
in uveal melanoma. Speciﬁcally, several genes on
chromosome 3 are not preferentially methylated in
tumours with monosomy 3. However, we found
methylation of the TSGs CDKN2A and RARB
in 7.5% of primary tumours. While promoter
methylation, as well as homozygous deletions, of
CDKN2A have been reported previously in uveal
melanomas (Merbs and Sidransky, 1999; van der
Velden et al., 2001), this is the ﬁrst report showing
methylation alterations of the RARB gene in this
tumour. Therefore, we suggest that this gene may
play a role in uveal melanoma formation.
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